Results 51 to 60 of about 281,748 (215)
Blood, 2019 Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
A. Yacoub +33 more
semanticscholar +1 more source
Primary myelofibrosis with increased haemoglobin concentration at presentation
British Journal of Haematology, EarlyView.Subjects with primary myelofibrosis and elevated haemoglobin levels at diagnosis tend to have longer survival rates (OS) and blast transformation‐free survival (BTFS) than those with normal or reduced haemoglobin levels. Summary One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin ...
Giovanni Barosi +8 more
wiley +1 more source
The Impact of Current Treatment on The Symptomatology and Complications of Patients with Polycythemia Vera [PDF]
Documenta HaematologicaIntroduction: polycythemia vera is a Ph-negative relatively indolent chronic myeloproliferative disease, with a high risk of arterial and venous thrombosis, affecting patient survival.
Marc-Tudor DAMIAN +2 more
doaj +1 more source
Blood Advances, 2019 In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET).
A. Carobbio +5 more
semanticscholar +1 more source
British Journal of Haematology, EarlyView.Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6‐month follow‐up period.
Ryan Brown +13 more
wiley +1 more source
Isolated cerebellar infarction in a case of JAK 2 mutation-negative polycythemia vera: A case report
Brain Circulation, 2022 Polycythemia vera is a myeloproliferative disorder caused by clonal expansion of erythroid precursors in the bone marrow commonly due to a mutation in the Janus kinase 2 (JAK2) gene located in the short arm of chromosome 9. Hyperviscosity of blood due to
Prasad Krishnan
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Previous studies investigating the role of TP53 mutations in chronic phase MPN have yielded inconsistent results. As such, the clinical relevance of these mutations remains to be elucidated. We report a case of a 67‐year‐old woman with a leukemic transformation of a post‐polycythaemia vera myelofibrosis (post‐PV MF) that culminated in the rare
Isidor Minović +8 more
wiley +1 more source
Polycythemia: A Clinical Approach
Jurnal Penyakit Dalam Indonesia, 2019 Polycythemia or erythrocytosis is an increase in the number of red blood cells in circulation marked by the increase in hematocrit. Polycythemia is a case that still raises questions and dilemma for doctors.
Rahmat Cahyanur, Ikhwan Rinaldi
doaj +1 more source
Thromboembolic events in polycythemia vera
Annals of Hematology, 2019 Thromboembolic events and cardiovascular disease are the most prevalent complications in patients with polycythemia vera (PV) compared with other myeloproliferative disorders and are the major cause of morbidity and mortality in this population. Moreover,
M. Griesshammer, J. Kiladjian, C. Besses
semanticscholar +1 more source
Journal of Internal Medicine, EarlyView.Abstract Background Clonal hematopoiesis (CH) is associated with adverse outcomes. We hypothesized that CH (JAK2V617F and CALR) is associated with cancer, vascular disease, and all‐cause mortality, even at a variant allele frequency (VAF) <1%. Methods We screened 19,832 individuals from the Danish General Suburban Population Study for JAK2V617F and ...
Morten Kranker Larsen +17 more
wiley +1 more source